N@N

Theravance, Inc.: Theravance to Report Second Quarter 2009 Financial Results on July 23, 2009

_{//health-fitness.news-articles.net/content/2009/ .. rter-2009-financial-results-on-july-23-2009.html}
^{Published in Health and Fitness on Thursday, July 9th 2009 at 13:23 GMT, Last Modified on 2009-11-02 11:52:43 by Market Wire}  

SOUTH SAN FRANCISCO, CA--(Marketwire - July 9, 2009) - Theravance, Inc. (NASDAQ: [ THRX ]) announced today that it will release financial results for the period ended June 30, 2009 after market close on Thursday, July 23, 2009.

An accompanying conference call will be held at 5:00 p.m. Eastern Daylight Time. To participate in the live call by telephone, please dial 877-440-5788 from the U.S., or 719-325-4937 for international callers. Those interested in listening to the conference call live via the internet may do so by visiting the company's web site at [ www.theravance.com ]. To listen to the live call, please go to the web site 15 minutes prior to its start to register, download, and install any necessary audio software.

A replay of the conference call will be available on the company's web site for 30 days through August 22, 2009. An audio replay will also be available through 11:59 p.m. Eastern Daylight Time on August 6, 2009 by dialing 888-203-1112 from the U.S., or 719-457-0820 for international callers, and entering confirmation code 7640818.

About Theravance

Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections and gastrointestinal motility dysfunction. The company's key programs include: telavancin for the treatment of serious Gram-positive bacterial infections with Astellas Pharma Inc. and the Horizon program and Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program with GlaxoSmithKline plc. By leveraging its proprietary insight of multivalency toward drug discovery focused primarily on validated targets, Theravance is pursuing a next generation strategy designed to discover superior medicines in areas of significant unmet medical need. For more information, please visit the company's web site at [ www.theravance.com ].

THERAVANCE®, the Theravance logo, and MEDICINES THAT MAKE A DIFFERENCE® are registered trademarks of Theravance, Inc.